title: Non-aromatic naphthalane preparation; preliminary clinical study in the treatment of psoriasis vulgaris.
abstract: This study aimed to prove the similarity of the composition of non-aromatic Croatian naphthalane (NAN) with brown naphthalane (BN), which is used in the treatment of psoriasis vulgaris. The comparison of the compositions was performed by obtaining GC fingerprints, which were supported by GC-MS data. In spite of remarkable differences in general profiles of the GC chromatograms, lower and medium molecular weight components of NAN were found to be qualitatively the same as the saturated constituents of BN. Quantitatively, lower molecular weight components as well as all n-alkanes were comparatively lower in NAN. NAN, additionally, contained higher molecular weight components, among which there were saturated oligocyclic hydrocarbons (up to pentakishomohopanes), described as responsible for the curing effect of naphthalane. The composition characteristics of NAN including its non-aromatic character made it suitable for a clinical study. In the treatment, the efficacy was determined by means of comparison of Psoriasis Area Severity Indices, PASI, at the beginning and at the end of the therapy. Adult volunteer-patients, nine males and six females, applied NAN over the whole body, except the scalp, at the room temperature for 20 min and this was followed by the selective UVB radiation. After the 3-week therapy, all essential clinical manifestations as erythema, desquamation and infiltration were significantly reduced in 14 patients; in nine cases the improvement was 50-93%, while the state of five patients improved between 25 and 50%. In one case, there was no obvious change. No exacerbation occurred during the therapy period. No adverse effect on hematological or biochemical parameters was noticed.
authors.affiliation: Department of Oral Medicine, Faculty of Dentistry, University of Zagreb, Gunduliceva 5, 10 000, Zagreb, Croatia. alajbeg@vip.hr
authors.forename: I
authors.initials: I
authors.lastname: Alajbeg
authors.forename: G
authors.initials: G
authors.lastname: Krnjević-Pezić
authors.forename: A
authors.initials: A
authors.lastname: Smeh-Skrbin
authors.forename: P
authors.initials: P
authors.lastname: Vrzogić
authors.forename: V
authors.initials: V
authors.lastname: Vucićević-Boras
authors.forename: I
authors.initials: I
authors.lastname: Dobrić
authors.forename: A
authors.initials: A
authors.lastname: Cekić-Arambasin
mesh_terms: D000328:Adult; D001494:Baths; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D008401:Gas Chromatography-Mass Spectrometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009281:Naphthalenes / Q000009:adverse effects / Q000032:analysis / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D013056:Spectrophotometry, Ultraviolet; D014466:Ultraviolet Rays
chemical_list: D003879:Dermatologic Agents; D009281:Naphthalenes; C007229:decalin